Evidence map›Paper›PMID 27865213›Full record

ArticleStem cell research & therapy2016

Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector.

Santhosh Chakkaramakkil Verghese, Natalya A Goloviznina, Peter Kurre

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Santhosh Chakkaramakkil VergheseDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA. chakkara@ohsu.edu.
Natalya A GolovizninaDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA.
Peter KurreDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, 97239, USA.
Oregon Health & Science University · US

Funding

HSC transduction in situ by cellular delivery of integrating viral vectorsR01HL090765 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KURRE, PETER · 2008 to 2013
$2.1M
Stem Cell Biology Training ProgramT32GM113846 · NIGMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2015 to 2019
$712k
NHLBI NIH HHS R01 HL090765NIGMS NIH HHS T32 GM113846
6 · The paper itself

Abstract

Fanconi anemia (FA) is an autosomal-recessive disorder associated with hematopoietic failure and it is a candidate for hematopoietic stem cell (HSC)-directed gene therapy. However, the characteristically reduced HSC numbers found in FA patients, their ineffective mobilization from the marrow, and re-oxygenation damage during ex vivo manipulation have precluded clinical success using conventional in vitro approaches. We previously demonstrated that lentiviral vector (LV) particles reversibly attach to the cell surface where they gain protection from serum complement neutralization. We reasoned that cellular delivery of LV to the bone marrow niche could avoid detrimental losses during FA HSC mobilization and in vitro modification. Here, we demonstrate that a VSV-G pseudotyped lentivector, carrying the FANCC transgene, can be transmitted from carrier to bystander cells. In cell culture and transplantation models of FA, we further demonstrate that LV carrier cells migrate along SDF-1α gradients and transfer vector particles that stably integrate and phenotypically correct the characteristic DNA alkylator sensitivity in murine and human FA-deficient target bystander cells. Altogether, we demonstrate that cellular homing mechanisms can be harnessed for the functional phenotype correction in murine FA hematopoietic cells.

Indexed as

AnimalsBone MarrowCell LineFanconi AnemiaFanconi Anemia Complementation Group C ProteinGenetic TherapyGenetic VectorsGene Transfer TechniquesHEK293 CellsHematopoietic Stem CellsHumansLentivirusMiceMice, Inbred C57BLMice, TransgenicPhenotypeFanconi Anemia Complementation Group C ProteinFA gene therapyFanconi AnemiaGene TherapyHematopoietic stem cellsIn situ gene deliveryLentiviral vector

Identifiers

PMID27865213
PMCPMC5116221
OpenAlexW2553373655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.